England's NICE Backs Vertex’s CF Drugs Kaftrio, Symkevi & Orkambi After Initial Rejection

 
• By Eliza Slawther

Cystic fibrosis patients in England will be able to access Vertex’s three combination therapies after the company announced an extended reimbursement agreement with the National Health Service and a positive opinion from the country’s HTA body, NICE.

Cystic Fibrosis
• Source: Shutterstock

More from Market Access

More from Pink Sheet